Terms: = Lung cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
1781 results:
1. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn's and Colitis (IRCC).
Saberzadeh-Ardestani B; Khosravi AA; Mansour-Ghanaei F; Vahedi H; Baniasadi N; Seyyedmajidi M; Parhizkar B; Hormati A; Naghshbandi SJ; Matin S; Hassan Zadeh AA; Taghvaei T; Bahrami M; Rafeey M; Ahadi M; Vossoughinia H; Muosavi H; Gheibi S; Hosseini-Hemmatabadi RS; Yazdanbod A; Matinkhah S; Sheikh Esmaeili F; Fakheri H; Moosavy SH; Maleki I; Nasseri-Moghaddam S; Khosravi B; Farahmand F; Najafi M; Alimadadi H; Malekzadeh M; Anushiravani A; Kasaeian A; Alatab S; Sadeghi A; Radmard AR; Kolahdoozan S; Rajabi Z; Sima AR
Arch Iran Med; 2024 Apr; 27(4):183-190. PubMed ID: 38685844
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis.
Zheng H; Tan J; Qin F; Zheng Y; Yang X; Qin X; Liao H
BMC Med Genomics; 2024 Apr; 17(1):97. PubMed ID: 38649961
[TBL] [Abstract] [Full Text] [Related]
3. The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
Cheng B; Li C; Li J; Gong L; Liang P; Chen Y; Zhan S; Xiong S; Zhong R; Liang H; Feng Y; Wang R; Wang H; Zheng H; Liu J; Zhou C; Shao W; Qiu Y; Sun J; Xie Z; Liang Z; Yang C; Cai X; Su C; Wang W; He J; Liang W
Signal Transduct Target Ther; 2024 Apr; 9(1):93. PubMed ID: 38637495
[TBL] [Abstract] [Full Text] [Related]
4. EIF4A3 modulated circ_000999 promotes epithelial-mesenchymal transition in cadmium-induced malignant transformation through the miR-205-5p/ZEB1 axis.
Wang D; Chen S; Shao Y; Deng Y; Huang L
Environ Int; 2024 Apr; 186():108656. PubMed ID: 38621321
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of miR-155 silencing using a molecular beacon in human lung adenocarcinoma cell line.
Alexandre D; Fernandes AR; Baptista PV; Cruz C
Talanta; 2024 Jul; 274():126052. PubMed ID: 38608633
[TBL] [Abstract] [Full Text] [Related]
6. "Decoding inflammation: glycoprotein a repetition predominant, microRNA-142-3-p, and metastasis associated lung adenocarcinoma transcript 1: as novel inflammatory biomarkers of inflammatory bowel disease".
Lahimchi MR; Mohammadnia-Afrouzi M; Baharlou R; Haghmorad D; Abedi SH; Arjmandi D; Hosseini M; Yousefi B
Mol Biol Rep; 2024 Apr; 51(1):500. PubMed ID: 38598005
[TBL] [Abstract] [Full Text] [Related]
7. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H; Chamoto K; Hatae R; Kurosaki T; Togashi Y; Fukuoka K; Goto M; Chiba Y; Tomida S; Ota T; Haratani K; Takahama T; Tanizaki J; Yoshida T; Iwasa T; Tanaka K; Takeda M; Hirano T; Yoshida H; Ozasa H; Sakamori Y; Sakai K; Higuchi K; Uga H; Suminaka C; Hirai T; Nishio K; Nakagawa K; Honjo T
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557498
[TBL] [Abstract] [Full Text] [Related]
8. Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
Tan AC; Cook SL; Khasraw M
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557495
[TBL] [Abstract] [Full Text] [Related]
9. Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma.
Hao Y; Yang J; Liu D; Zhang H; Ou T; Xiao L; Chen W
Biomed Pharmacother; 2024 May; 174():116506. PubMed ID: 38554525
[TBL] [Abstract] [Full Text] [Related]
10. Role of CD38 in anti-tumor immunity of small cell lung cancer.
Taniguchi H; Chavan SS; Chow A; Chan JM; Mukae H; Rudin CM; Sen T
Front Immunol; 2024; 15():1348982. PubMed ID: 38533509
[TBL] [Abstract] [Full Text] [Related]
11. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P; Thummalapalli R; Betti MJ; Yao L; Quandt Z; Balaratnam K; Bejan CA; Cardenas E; Falcon CJ; Faleck DM; ; Gubens MA; Huntsman S; Johnson DB; Kachuri L; Khan K; Li M; Lovly CM; Murray MH; Patel D; Werking K; Xu Y; Zhan LJ; Balko JM; Liu G; Aldrich MC; Schoenfeld AJ; Ziv E
Nat Commun; 2024 Mar; 15(1):2568. PubMed ID: 38531883
[TBL] [Abstract] [Full Text] [Related]
12. KN046, a bispecific antibody against PD-L1 and ctla-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial.
Zhao Y; Chen G; Li X; Wu J; Chang B; Hu S; Yang S; Xu T; Liu Y; Wang N; Zhang L; Huang Y
Cell Rep Med; 2024 Mar; 5(3):101470. PubMed ID: 38508135
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Efficacy and Gut Microbiota Regulating-Related Effect of Si-Jun-Zi Decoction in Postoperative Non-Small Cell lung cancer Patients: A Prospective Observational Study.
He Y; Qi A; Gu Y; Zhang C; Wang Y; Yang W; Bi L; Gong Y; Jiao L; Xu L
Integr Cancer Ther; 2024; 23():15347354241237973. PubMed ID: 38504436
[TBL] [Abstract] [Full Text] [Related]
14. Immunotherapy in Non-small Cell lung cancer: a Review.
Sequeira T; Almodovar MT
Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):55-65. PubMed ID: 38499025
[TBL] [Abstract] [Full Text] [Related]
15. Longitudinal Study on Changes of cancer-Related Fatigue in Elderly Patients with Postoperative Chemotherapy for Non-Small Cell lung cancer.
Wang T; Wang Y; Luo Y; Chen H
Ann Ital Chir; 2024; 95(1):22-29. PubMed ID: 38469616
[TBL] [Abstract] [Full Text] [Related]
16. East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: An updated meta-analysis.
Yao Y; Li B; Xu Y; Yang L; Zou B; Wang L
Cancer Med; 2024 Feb; 13(4):e7080. PubMed ID: 38457254
[TBL] [Abstract] [Full Text] [Related]
17. The p38 MAPK/snail signaling axis participates in cadmium-induced lung cancer cell migration and invasiveness.
Hu M; Xu J; Shi L; Shi L; Yang H; Wang Y
Environ Sci Pollut Res Int; 2024 Apr; 31(16):24042-24050. PubMed ID: 38436850
[TBL] [Abstract] [Full Text] [Related]
18. Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data.
Lippenszky L; Mittendorf KF; Kiss Z; LeNoue-Newton ML; Napan-Molina P; Rahman P; Ye C; Laczi B; Csernai E; Jain NM; Holt ME; Maxwell CN; Ball M; Ma Y; Mitchell MB; Johnson DB; Smith DS; Park BH; Micheel CM; Fabbri D; Wolber J; Osterman TJ
JCO Clin Cancer Inform; 2024 Feb; 8():e2300207. PubMed ID: 38427922
[TBL] [Abstract] [Full Text] [Related]
19. Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET.
Zader JA; Jörres RA; Mayer I; Alter P; Bals R; Watz H; Mertsch P; Rabe KF; Herth F; Trudzinski FC; Welte T; Kauczor HU; Behr J; Walter J; Vogelmeier CF; Kahnert K
BMC Pulm Med; 2024 Mar; 24(1):103. PubMed ID: 38424530
[TBL] [Abstract] [Full Text] [Related]
20. Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma.
Hao B; Dong H; Xiong R; Song C; Xu C; Li N; Geng Q
Comput Biol Med; 2024 Mar; 171():108183. PubMed ID: 38422959
[TBL] [Abstract] [Full Text] [Related]
[Next]
